HER-2/neu overexpression detected by immunohistochemistry in soft tissue sarcomas

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 2, 2003, Pages 188-191

  Foster, Heidi ^a   Knox, Stacey ^a   Ganti, Apar Kishor ^a   Hebert, Brian J ^a   Koch, Michael ^b   Tendulkar, Ketki ^a   Levitt, Ralph ^c   Potti, Anil ^a  

^a UND School of Medicine & Health Sciences Southeast Campus   (United States)

^b MeritCare Hospital   (United States)

^c MeritCare Roger Maris Cancer Center   (United States)

Author keywords

Carcinosarcoma; Dermatofibrosarcoma; Her 2 neu overexpression; Malignant fibrous histiocytoma; Soft tissue sarcoma

Indexed keywords

PARAFFIN; TRASTUZUMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOSARCOMA; CHILD; CONTROLLED STUDY; DERMATOFIBROMA; FEMALE; GENE OVEREXPRESSION; HISTIOCYTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PROGNOSIS; SARCOMA; SCORING SYSTEM; SOFT TISSUE SARCOMA; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOSARCOMA; CHILD; CHILD, PRESCHOOL; DERMATOFIBROSARCOMA; FEMALE; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LEIOMYOSARCOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL ANALYSIS;

EID: 0037392971     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200304000-00018     Document Type: Article

References (30)

1. Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol 1997;24:556-60.
2. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol 1999;26(suppl 12):51-9.
3. Potti A, Ganti AK, Koch M, et al. Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in nonsmokers with chronic lymphocytic leukemia. Lung Cancer 2001;34:227-32.
4. Potti A, Willardson J, Forseen C, et al. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer 2002 Jun;36(3):257-61.
5. Schneider PM, Hung MC, Chiocca SM, et al. Differential expression of the c-erbB-2 gene in human small cell and non-small lung cell cancer. Cancer Res 1989;49:4968-71.
6. Weiner DB, Nordberg J, Robinson R, et al. Expression of neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 1990;50:421-5.
7. Zhang X, Silva E, Greshenson D, et al. Amplification and rearrangement of c-erbB proto-oncogenes in cancer of human female genital tract. Oncogene 1989;4:985-9.
8. Yokota J, Yamamoto T, Miyajima N, et al. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1988;2:283-7.
9. Riben MW, Malfetano JH, Nazeer T, et al. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Mod Pathol 1997;10:823-31.
10. Costa MJ, Walls J. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed Mullerian tumors). Clinicopathologic study of 82 cases. Cancer 1996;77:533-42.
11. Dugan MC, Dergham ST, Kucway R, et al. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas 1997;14:229-36.
12. Kapitanovic S, Radosevic S, Kapitanovic M, et al. The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997;112:1103-13.
13. Costa MJ, Walls J, Trelford JD. C-erbB-2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease. Am J Clin Pathol 1995;104:634-42.
14. Mellemgaard A, Geisler CH, Storm HH. Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemias. Eur J Haematol 1994;53:218-22.
15. Yu D, Liu B, Tan M, et al. Over-expression of c-erbB-2/neu I breast cancer cells confers increased resistance to Taxol via mdr1-independent mechanisms. Oncogene 1996;13:1359-65.
16. McCann AH, Dervan PA, O'Regan M, et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991;51:3296-303.
17. Slamon DJ, Clark GK, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987;235:177-82.
18. Gusterson BA, Gelber RD, Goldrisch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:1049-56.
19. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin as a single agent in 222 women with HER-2 overexpression who relapsed following chemotherapy for metastatic breast cancer [Abstract]. Proc Am Soc Clin Oncol 1998;17:97a.
20. Jimenez RE, Wallis T, Tabasczka P, et al. Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
21. Bluehler H, Bangemann N, Evers K, et al. Effective HER-2/neu diagnosis in breast cancer by a combination of immunochemistry and FISH [Abstract]. Proc Am Soc Clin Oncol 2000;19:76a.
22. Mass RD, Sanders C, Charlene K, et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials Abstract]. Proc Am Soc Clin Oncol 2000;19:75a.
23. Saunders BD, Trapp RG. Basic and clinical biostatistics. 2nd ed. Norwalk: Appleton and Lange, 1994:117-9.
24. Swisher EM, Gown AM, Skelly M, et al. The expression of epidermal growth factor receptor, HER-2/neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcomas. Gynecol Oncol 1996;60:81-8.
25. Mark BF, Brown S, Sun CL, et al. Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. Pathobiology 1998;66:59-63.
26. Oliveira AM, Medeiros F, Okuno SH, et al. HER-2/neu protein overexpression is a rare event in adult soft tissue sarcomas [Abstract]. Proc Am Soc Clin Oncol 2001;20:294b.
27. Wittig JC, Cruz L, Wodajo F, et al. Expression of HER2/neu (HER2) and EGFR in osteosarcoma [Abstract]. Proc Am Soc Clin Oncol 2001;20:98a.
28. Duda RB, Cundiff D, August CZ, et al. Growth factor receptor and related oncogene determination in mesenchymal tumors. Cancer 1993;71:3526-30.
29. George E, Niehans GA, Swanson PE, et al. Overexpression of the c-erbB-2 oncogene in sarcomas and small round-cell tumors of childhood. An immunohistochemical investigation. Arch Pathol Lab Med 1992;116:1033-5.
30. Nasu K, Kawano Y, Hirota Y, et al. Immunohistochemical study of c-erb B-2 expression in malignant mixed mullerian tumors of the female genital tract. J Obstet Gynaecol Res 1996;22:347-51.